Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon

2026-01-21 14:50:39 ET

The last time I spoke about Corvus Pharmaceuticals, Inc. ( CRVS ), it was in a Seeking Alpha article entitled " Corvus Pharmaceuticals: Positive Phase 1 Soquelitinib Trial Data Brings 2025 Catalysts. " With respect to this article, I noted that the company had obtained some positive results from its ongoing phase 1 study using its ITK inhibitor soquelitinib to treat patients with moderate-to-severe atopic dermatitis [AD]. I also mentioned that the company was set to release results from cohort 4 of this early-stage study as well....

Read the full article on Seeking Alpha

For further details see: